O	0	10	Randomized
O	10	11	,
O	12	18	double
O	18	19	-
O	19	24	blind
O	25	30	study
O	31	40	comparing
O	41	49	proposed
B-intervention	50	60	biosimilar
I-intervention	61	63	LA
I-intervention	63	64	-
I-intervention	64	70	EP2006
O	71	75	with
B-control	76	85	reference
I-control	86	99	pegfilgrastim
O	100	102	in
O	103	109	breast
O	110	116	cancer
O	116	117	.

O	118	122	This
O	123	133	randomized
O	133	134	,
O	135	141	double
O	141	142	-
O	142	147	blind
O	148	153	trial
O	154	162	compared
O	163	171	proposed
O	172	182	biosimilar
O	183	185	LA
O	185	186	-
O	186	192	EP2006
O	193	197	with
O	198	207	reference
O	208	221	pegfilgrastim
O	222	224	in
B-eligibility	225	230	women
I-eligibility	231	240	receiving
I-eligibility	241	253	chemotherapy
I-eligibility	254	257	for
I-eligibility	258	264	breast
I-eligibility	265	271	cancer
O	272	273	(
O	273	280	PROTECT
O	280	281	-
O	281	282	1
O	282	283	)
O	283	284	.

O	285	290	Women
O	291	292	(
B-age	292	293	≥
I-age	293	295	18
I-age	296	301	years
O	301	302	)
O	303	307	were
O	308	318	randomized
O	319	321	to
O	322	329	receive
O	330	332	LA
O	332	333	-
O	333	339	EP2006
O	340	341	(
O	341	342	n
O	343	344	=
B-intervention-participants	345	348	159
O	348	349	)
O	350	352	or
O	353	362	reference
O	363	364	(
O	364	365	n
O	366	367	=
B-control-participants	368	371	157
O	371	372	)
O	373	386	pegfilgrastim
O	387	388	(
O	388	396	Neulasta
O	396	397	(
O	397	398	®
O	398	399	)
O	399	400	,
O	401	406	Amgen
O	406	407	)
O	408	411	for
O	412	413	≤
O	413	414	6
O	415	421	cycles
O	422	424	of
O	425	426	(
O	426	429	neo
O	429	430	)
O	430	431	-
O	431	439	adjuvant
O	440	443	TAC
O	444	456	chemotherapy
O	456	457	.

O	458	465	Primary
O	466	469	end
O	470	475	point
O	476	479	was
B-outcome-Measure	480	488	duration
I-outcome-Measure	489	491	of
I-outcome-Measure	492	498	severe
I-outcome-Measure	499	510	neutropenia
I-outcome-Measure	511	512	(
I-outcome-Measure	512	515	DSN
I-outcome-Measure	515	516	)
I-outcome-Measure	517	523	during
I-outcome-Measure	524	529	cycle
I-outcome-Measure	530	531	1
O	532	533	(
O	533	539	number
O	540	542	of
O	543	554	consecutive
O	555	559	days
O	560	564	with
O	565	573	absolute
O	574	584	neutrophil
O	585	590	count
O	591	592	<
O	592	593	0
O	593	594	.
O	594	595	5
O	596	597	×
O	598	600	10
O	600	601	(
O	601	602	9
O	602	603	)
O	603	604	/
O	604	605	l
O	605	606	)
O	607	611	with
O	612	623	equivalence
O	624	633	confirmed
O	634	636	if
O	637	639	90
O	639	640	%
O	641	644	and
O	645	647	95
O	647	648	%
O	649	652	CIs
O	653	657	were
O	658	664	within
O	665	666	a
O	667	668	±
O	668	669	1
O	670	673	day
O	674	680	margin
O	680	681	.

O	682	685	For
B-outcome	686	689	DSN
O	689	690	,
O	691	693	LA
O	693	694	-
O	694	700	EP2006
O	701	704	was
O	705	715	equivalent
O	716	718	to
O	719	728	reference
O	729	730	(
O	730	740	difference
O	740	741	:
O	742	743	0
O	743	744	.
O	744	746	07
O	747	751	days
O	751	752	;
O	753	755	90
O	755	756	%
O	757	759	CI
O	759	760	:
O	761	762	-
O	762	763	0
O	763	764	.
O	764	766	09
O	766	767	-
O	767	768	0
O	768	769	.
O	769	771	23
O	771	772	;
O	773	775	95
O	775	776	%
O	777	779	CI
O	779	780	:
O	781	782	-
O	782	783	0
O	783	784	.
O	784	786	12
O	786	787	-
O	787	788	0
O	788	789	.
O	789	791	26
O	791	792	)
O	792	793	.

O	794	796	LA
O	796	797	-
O	797	803	EP2006
O	804	807	and
O	808	817	reference
O	818	831	pegfilgrastim
O	832	838	showed
O	839	841	no
O	842	852	clinically
O	853	863	meaningful
O	864	875	differences
O	876	885	regarding
O	886	894	efficacy
O	895	898	and
O	899	905	safety
O	906	908	in
O	909	915	breast
O	916	922	cancer
O	923	931	patients
O	932	941	receiving
O	942	954	chemotherapy
O	954	955	.
